Financial Performance - Generated record quarterly net revenue of $209.4 million, up 31% year-over-year[1] - Generated record quarterly pain portfolio net revenue of $167.6 million, up 11% year-over-year, with all three core products growing year-over-year[5] - Generated Nucynta franchise net revenue of $54.8 million, up 21% year-over-year[8] - Adjusted EBITDA for Q3 2025 was $133.0 million, representing a 27% increase year-over-year[10] - GAAP net income for Q3 2025 was $31.5 million, with $1.00 GAAP earnings per share (basic)[9] - Net income for Q3 2025 was $31.5 million, significantly up from $9.3 million in Q3 2024, marking a 237.5% increase[28] - Adjusted EBITDA for Q3 2025 was $133.0 million, compared to $105.1 million in Q3 2024, representing a 26.5% increase[30] - The company reported a basic earnings per share of $1.00 for Q3 2025, compared to $0.29 for Q3 2024, reflecting a significant increase[28] Revenue Guidance - Raised full-year 2025 net revenue guidance to a range of $775 to $785 million and adjusted EBITDA guidance to a range of $460 to $470 million[1][6] - Collegium Pharmaceutical anticipates continued growth in product revenues and adjusted EBITDA for 2025, driven by market expansion and new product launches[1] Cash and Assets - Ended Q3'25 with cash, cash equivalents, and marketable securities of $285.9 million[1] - Total assets as of September 30, 2025, were $1.607 billion, a decrease from $1.664 billion as of December 31, 2024[26] - Cash and cash equivalents increased to $150.1 million from $70.6 million at the end of 2024, showing a 112.5% increase[26] Operating Expenses - Adjusted operating expenses for Q3 2025 were $55.7 million, representing a 60% increase year-over-year[9] - Selling, general and administrative expenses for Q3 2025 were $67.1 million, up from $62.0 million in Q3 2024, indicating an 8.5% increase[28] Product Performance - Generated record quarterly Jornay PM® net revenue of $41.8 million, with prescriptions growing by 20% year-over-year[5] - Jornay PM prescribers reached an all-time high of 27,700 healthcare providers, up 22% year-over-year[5] - Product revenues for Q3 2025 reached $209.4 million, a 31.5% increase from $159.3 million in Q3 2024[28] - Gross profit for Q3 2025 was $129.2 million, compared to $96.8 million in Q3 2024, reflecting a 33.4% year-over-year growth[28] Strategic Focus - The company is focused on managing relationships with licensors and maintaining regulatory approvals to support future growth[1]

Financial Performance - Consolidated revenue for Q1 FY 2026 was $328.8 million, up from $292.3 million in Q1 FY 2025, representing a 12.5% increase[1] - Consolidated net loss for Q1 FY 2026 was $30.5 million, an improvement from a net loss of $44.5 million in Q1 FY 2025[1] - Adjusted EBITDA for Q1 FY 2026 was $(32.1) million, compared to $(1.7) million in Q1 FY 2025[1] - The net loss attributable to common shareholders for the quarter was $47.9 million, compared to a net loss of $44.5 million in the same quarter last year[38] - Net loss for Q3 2025 was $30,459,000, a decrease from a net loss of $44,546,000 in Q3 2024, representing a 31.6% improvement[45] - Total revenue from reportable segments in Q3 2025 was $326,994,000, compared to $287,937,000 in Q3 2024, reflecting a 13.6% increase[41] - Adjusted EBITDA for Q3 2025 was $(32,079,000), compared to $(1,683,000) in Q3 2024, indicating a significant decline in profitability[45] Segment Performance - The Senior segment reported revenue of $59.0 million, down 37% from $92.9 million in the same period last year[6] - The Healthcare Services segment generated revenue of $221.4 million, a 42% increase from $155.7 million in Q1 FY 2025[14] - The Life segment reported revenue of $46.6 million, a 19% increase from $39.3 million in Q1 FY 2025[23] - Pharmacy revenue reached $218.5 million, up 43% from $152.9 million year-over-year[38] - Adjusted Segment EBITDA for Healthcare in Q3 2025 was $7,212,000, down from $7,724,000 in Q3 2024, a decrease of 6.6%[41] Customer Metrics - The number of SelectRx members increased by 24% year-over-year, reaching 106,914 members as of September 30, 2025[16] - The revenue to customer acquisition cost (CAC) ratio reached an all-time high of 6.4x, nearly 40% higher than the previous year[2] - Approved Medicare Advantage policies decreased by 32% to 62,510 in Q1 FY 2026 from 91,680 in Q1 FY 2025[11] Financial Outlook - The company maintains its fiscal 2026 financial outlook of $1.65 to $1.75 billion in revenue and $120 to $150 million in Adjusted EBITDA[4] Cash Flow and Assets - Cash used in operating activities for Q3 2025 was $21,623,000, compared to $16,610,000 in Q3 2024, showing an increase in cash outflow[45] - Cash and cash equivalents at the end of Q3 2025 were $15,699,000, down from $42,690,000 at the beginning of the period[45] - Total current assets decreased to $332.0 million from $341.0 million as of June 30, 2025[36] - Total liabilities as of September 30, 2025, were $660.1 million, a decrease from $673.8 million as of June 30, 2025[37] - Commissions receivable-current increased to $193.4 million from $132.1 million, indicating growth in expected revenue[36] Business Structure - The company has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life, focusing on various insurance and healthcare services[33] Other Financial Metrics - The company reported a loss from operations of $40.7 million for the quarter, compared to a loss of $12.0 million in the prior year[38] - SelectQuote's accumulated deficit increased to $252.6 million as of September 30, 2025, from $222.2 million as of June 30, 2025[37] - Proceeds from the revolving credit facility in Q3 2025 were $80,000,000, with payments of $65,000,000, resulting in a net increase of $15,000,000[45] - Total cash used in investing activities for Q3 2025 was $3,984,000, an increase from $2,574,000 in Q3 2024[45] - The company reported a change in fair value of warrants of $(15,036,000) in Q3 2025, compared to no such change in Q3 2024[45]

Exhibit 99.1 Cronos Group Reports 2025 Third Quarter Results Achieved record levels of consolidated net revenue, gross profit and Adjusted EBITDA Net revenue in Q3 2025 increased by 9% quarter-over-quarter and 6% year-over-year Generated record-high net revenue in Israel, where PEACE NATURALS remains the number one cannabis brand ® 1 Industry-leading balance sheet with $824 million in total cash and cash equivalents and short-term investments TORONTO, November 6, 2025 - Cronos Group Inc. (NASDAQ: CRON) (TSX ...

Revenue Performance - Revenue decreased 5 percent to $1.3 billion, with North American revenue declining 8 percent to $792 million and international revenue growing 2 percent to $551 million[3] - Net revenues for the three months ended September 30, 2025, were $1,333,380, a decrease of 4.7% compared to $1,399,023 in the same period of 2024[17] - North America segment revenues decreased by 8.3% to $791,502 for the three months ended September 30, 2025, compared to $863,345 in 2024[17] - EMEA segment revenues increased by 12.2% to $317,679 for the three months ended September 30, 2025, compared to $283,178 in 2024[17] - Total net revenue growth (decline) for the six months ended September 30, 2025, was (4.5)%, with a currency-neutral net revenue decline of (5.2)%[29] Profitability Metrics - Gross margin declined by 250 basis points to 47.3 percent, primarily due to supply chain headwinds and increased tariffs[3] - Gross profit for the three months ended September 30, 2025, was $630,584, representing 47.3% of net revenues, down from 49.8% in 2024[17] - Operating income was $17 million, while adjusted operating income, excluding transformation expenses and restructuring charges, was $53 million[3] - Projected operating income for fiscal 2026 is expected to range from $19 million to $34 million, with adjusted operating income forecasted between $90 million and $105 million[7] - Adjusted income from operations for the six months ended September 30, 2025, was $77,806 thousand, compared to $174,077 thousand for the same period in 2024[33] Net Income and Loss - Net loss was $19 million, with adjusted net income reported at $15 million[3] - Net income for the three months ended September 30, 2025, was a loss of $18,814, compared to a net income of $170,382 in 2024[17] - For the six months ended September 30, 2025, the net income was $(21,426) thousand, compared to $(135,044) thousand for the same period in 2024, indicating an improvement[27] - The company reported an adjusted net income of $23,854 thousand for the six months ended September 30, 2025, compared to $134,770 thousand for the same period in 2024[35] Expenses - Selling, general, and administrative (SG&A) expenses increased 12 percent to $582 million, with adjusted SG&A expenses rising 9 percent to $577 million[3] - The company reported a restructuring charge of $31,906 for the three months ended September 30, 2025, compared to $3,212 in 2024[17] - Adjusted selling, general and administrative expenses for the six months ended September 30, 2025, were $1,099,274 thousand, compared to $1,084,730 thousand for the same period in 2024[31] Cash Flow and Financial Position - Cash and cash equivalents totaled $396 million, with inventory declining 6 percent to $1.0 billion[6] - Total current assets increased to $2,943,783 as of September 30, 2025, from $2,329,097 as of March 31, 2025[25] - Total liabilities rose to $3,043,800 as of September 30, 2025, compared to $2,410,593 as of March 31, 2025[25] - Cash flows from operating activities for the six months ended September 30, 2025, were $(20,978) thousand, an improvement from $(168,409) thousand in the same period of 2024[27] - Net cash provided by financing activities for the six months ended September 30, 2025, was $560,462 thousand, compared to $(129,392) thousand for the same period in 2024[27] Shareholder Actions and Future Outlook - The company repurchased $25 million of its Class C common stock, retiring 5.2 million shares as part of a $500 million share buyback program[4] - Fiscal 2026 outlook projects revenue to decrease 4 to 5 percent, with anticipated declines in North America and Asia-Pacific, and a high-single-digit percentage increase in EMEA[7] - Expected gross margin decline of 190 to 210 basis points, mainly due to higher U.S. tariffs and unfavorable channel mix[7] - The outlook for the year ending March 31, 2026, estimates adjusted income from operations to be between $90 million and $105 million[40] - The adjusted diluted net income per share for the year ending March 31, 2026, is projected to be between $0.03 and $0.05[41] Operational Metrics - The company maintained a total of 447 doors as of September 30, 2025, compared to 446 doors as of September 30, 2024[43] - Direct-to-consumer revenues decreased by 2.2% to $538,136 for the three months ended September 30, 2025, compared to $550,336 in 2024[19]

Revenue Performance - Revenue decreased 5 percent to $1.3 billion, with North American revenue declining 8 percent to $792 million and international revenue growing 2 percent to $551 million[3] - Net revenues for the three months ended September 30, 2025, were $1,333,380, a decrease of 4.7% compared to $1,399,023 in the same period of 2024[17] - North America segment revenues decreased by 8.3% to $791,502 for the three months ended September 30, 2025, compared to $863,345 in 2024[17] - Direct-to-consumer revenues decreased by 2.2% to $538,136 for the three months ended September 30, 2025, compared to $550,336 in 2024[19] - Total net revenue growth (decline) for the six months ended September 30, 2025, was (4.5)%, with a currency-neutral net revenue decline of (5.2)%[29] Profitability and Margins - Gross margin declined by 250 basis points to 47.3 percent, primarily due to supply chain headwinds and increased tariffs[3] - Gross profit for the three months ended September 30, 2025, was $630,584, representing 47.3% of net revenues, down from 49.8% in 2024[17] - Operating income was $17 million, while adjusted operating income, excluding transformation expenses and restructuring charges, was $53 million[3] - Projected operating income for fiscal 2026 is expected to range from $19 million to $34 million, with adjusted operating income forecasted between $90 million and $105 million[7] - Adjusted income from operations for the six months ended September 30, 2025, was $77,806 thousand, compared to $174,077 thousand in 2024[33] Net Income and Loss - Net loss was $19 million, with adjusted net income reported at $15 million[3] - The company reported a net loss of $18,814 for the three months ended September 30, 2025, compared to a net income of $170,382 in 2024[17] - For the six months ended September 30, 2025, the net income was $(21,426) thousand, compared to $(135,044) thousand for the same period in 2024, indicating an improvement[27] - The company reported an adjusted net income of $23,854 thousand for the six months ended September 30, 2025, compared to $134,770 thousand in 2024[35] Expenses - Selling, general, and administrative (SG&A) expenses increased 12 percent to $582 million, with adjusted SG&A expenses rising 9 percent to $577 million[3] - The company experienced a significant increase in restructuring charges, which amounted to $31,906 for the three months ended September 30, 2025, compared to $3,212 in 2024[17] - Adjusted selling, general and administrative expenses for the six months ended September 30, 2025, were $1,099,274 thousand, compared to $1,084,730 thousand in 2024[31] Cash and Assets - Cash and cash equivalents totaled $396 million, with inventory declining 6 percent to $1.0 billion[6] - Total current assets increased to $2,943,783 as of September 30, 2025, from $2,329,097 as of March 31, 2025[25] - Total liabilities rose to $3,043,800 as of September 30, 2025, compared to $2,410,593 as of March 31, 2025[25] - Cash flows from operating activities for the six months ended September 30, 2025, were $(20,978) thousand, an improvement from $(168,409) thousand in 2024[27] - Net cash provided by financing activities for the six months ended September 30, 2025, was $560,462 thousand, compared to $(129,392) thousand in 2024[27] Stock and Shareholder Actions - Under Armour repurchased $25 million of its Class C common stock, retiring 5.2 million shares during the quarter[4] - The outlook for the year ending March 31, 2026, estimates adjusted income from operations to be between $90 million and $105 million[40] - The adjusted diluted net income per share for the year ending March 31, 2026, is projected to be between $0.03 and $0.05[41] - The company maintained a total of 447 doors as of September 30, 2025, compared to 446 doors in the previous year[43]

Financial Performance - Alpha reported a net loss of $5.5 million for Q3 2025, compared to a net loss of $5.0 million in Q2 2025 and a net income of $3.8 million in Q3 2024[2][4]. - Total revenues for the nine months ended September 30, 2025, were $1.61 billion, down 31.2% from $2.34 billion in the same period of 2024[28]. - For the nine months ended September 30, 2025, the company reported a net loss of $44.416 million compared to a net income of $189.708 million for the same period in 2024[33]. - Basic loss per share for Q3 2025 was $0.42, compared to earnings of $0.29 per share in Q3 2024[28]. - The company reported a GAAP coal margin of $4.999 million for the nine months ended September 30, 2025, significantly lower than $271.018 million in 2024[39]. Revenue and Sales - Coal revenues for Q3 2025 were $525.2 million, a decrease of 21.6% from $669.8 million in Q3 2024[28]. - Coal revenues for the Met segment were $525.2 million in Q3 2025, a decrease from $548.7 million in Q2 2025[6]. - Non-GAAP coal revenues for the nine months ended September 30, 2025, were $1.353 billion, a decrease of 29.6% from $1.924 billion in 2024[39]. - The company sold 11,496 tons of coal in the nine months ended September 30, 2025, compared to 13,065 tons in 2024, reflecting a decrease of 12%[39]. - The non-GAAP coal sales realization per ton for the nine months ended September 30, 2025, was $117.66, down from $147.26 in 2024[39]. Costs and Expenses - The company reported a total cost of coal sales of $461.6 million for Q3 2025, a decrease of 22.9% from $598.7 million in Q3 2024[28]. - The total cost of coal sales for the nine months ended September 30, 2025, was $1.599 billion, down 22.3% from $2.060 billion in 2024[39]. - Selling, general and administrative expenses for the nine months ended September 30, 2025, were $46.3 million, down 18.9% from $57.2 million in the same period of 2024[28]. - The cost of coal sales for the Met segment decreased to $97.27 per ton in Q3 2025, compared to $100.06 per ton in Q2 2025[11][12]. Liquidity and Capital Expenditures - Total liquidity as of September 30, 2025, was $568.5 million, including cash and cash equivalents of $408.5 million[3][14]. - Cash and cash equivalents were $408.5 million as of September 30, 2025, down from $481.6 million at December 31, 2024[30]. - Capital expenditures for Q3 2025 were $25.1 million, down from $34.6 million in Q2 2025[13]. - The company experienced a net cash used in investing activities of $165.692 million for the nine months ended September 30, 2025, compared to $178.731 million in 2024[33]. Guidance and Future Commitments - Alpha is lowering its 2025 guidance range for capital contributions to equity affiliates to between $35 million and $41 million, down from $44 million to $54 million[17]. - Approximately 85% of metallurgical coal for 2025 has been committed and priced at an average price of $122.57 per ton[17]. - The company has authorized a share repurchase program of up to $1.5 billion, with approximately 6.8 million shares repurchased at a cost of about $1.1 billion as of October 31, 2025[15][16]. Asset and Liability Changes - Total current assets decreased to $989.9 million as of September 30, 2025, from $1.04 billion at December 31, 2024[30]. - Total liabilities decreased to $753.2 million as of September 30, 2025, from $789.2 million at December 31, 2024[30]. - Cash and cash equivalents at the end of the period were $534.315 million, down from $605.637 million at the end of September 2024[34]. EBITDA Performance - Adjusted EBITDA for the third quarter was $41.7 million, down from $46.1 million in the previous quarter[5]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $93.397 million, a decline of 73.6% from $354.599 million in 2024[36].

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update – Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Prior to April 2040 – ® ® – Bempedoic Acid Received Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dysl ...

Revenue Performance - Revenue for the fiscal fourth quarter of 2025 was $261.2 million, a 30.1% increase from $200.7 million in the same quarter of the previous year[6] - For fiscal year 2025, total revenue reached $967.3 million, a 32.6% increase from $729.6 million in fiscal year 2024[6] - Revenue for the three months ended October 3, 2025, was $261,170 million, a 3% increase from $252,079 million for the same period in 2024[29] - The company expects revenue for the fiscal first quarter of 2026 to be between $265 million and $273 million[8] Profitability Metrics - Net income for the fourth quarter was $45.1 million, or $0.59 per diluted share, compared to $29.4 million, or $0.39 per diluted share, in the previous year[6] - Adjusted net income for fiscal year 2025 was $263.4 million, or $3.47 per diluted share, compared to $188.2 million, or $2.56 per diluted share, in fiscal year 2024[6] - Net income for the three months ended October 3, 2025, was $45,120 million, compared to $36,534 million for the same period in 2024, representing a 23% increase[29] - Adjusted net income (Non-GAAP) for the twelve months ended October 3, 2025, was $263,372 million, representing 27.2% of revenue, up from $188,217 million (25.8%) year-over-year[35] Gross Margin and Profit - Gross margin for the fourth quarter was 54.5%, slightly down from 54.7% in the previous year[6] - Gross profit for the twelve months ended October 3, 2025, reached $529,002 million, compared to $393,773 million for the previous year, reflecting a 34% increase[29] - Gross profit for the three months ended October 3, 2025, was $142,301 million, representing 54.5% of revenue, compared to $139,436 million (55.3%) for the previous quarter[35] - Adjusted gross profit (Non-GAAP) for the twelve months ended October 3, 2025, was $555,289 million, accounting for 57.4% of revenue, up from $422,636 million (57.9%) year-over-year[35] Operating Expenses - Research and development expenses for the three months ended October 3, 2025, were $62,880 million, slightly down from $63,380 million in the prior quarter[29] - Operating expenses (GAAP) for the three months ended October 3, 2025, were $102,706 million, or 39.3% of revenue, compared to $101,776 million (40.4%) in the previous quarter[35] - Adjusted operating expenses (Non-GAAP) for the twelve months ended October 3, 2025, were $309,557 million, representing 32.0% of revenue, down from $247,603 million (33.9%) year-over-year[35] Strategic Initiatives - MACOM has made strategic acquisitions, including ENGIN-IC, Inc. and Linearizer Communications Group, to enhance its product offerings[11] - The company operates facilities across the United States, Europe, and Asia, servicing over 6,000 customers annually[10] - Management expressed confidence in starting fiscal 2026, building on the strong foundation established in fiscal year 2025[7] Balance Sheet and Cash Flow - Total current assets increased to $1,205,088 million as of October 3, 2025, from $903,078 million a year earlier, marking a 33% growth[31] - Cash and cash equivalents decreased to $112,142 million from $146,806 million year-over-year[31] - Net cash provided by operating activities for the twelve months ended October 3, 2025, was $235,368 million, up from $162,640 million in the previous year[33] - Total liabilities increased to $776,265 million as of October 3, 2025, compared to $629,297 million a year prior, indicating a 23% rise[31] - The company reported a loss on extinguishment of debt amounting to $193,098 million for the twelve months ended October 3, 2025[33] Shareholder Metrics - The weighted average diluted shares outstanding increased to 76,252 million for the three months ended October 3, 2025, from 75,864 million in the prior quarter[29] - Interest income (GAAP) for the three months ended October 3, 2025, was $8,016 million, or 3.1% of revenue, compared to $7,598 million (3.0%) in the previous quarter[36] - Adjusted interest income (Non-GAAP) for the twelve months ended October 3, 2025, was $25,786 million, accounting for 2.7% of revenue, compared to $18,996 million (2.6%) year-over-year[36]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 6, 2025 Commission File Number: 0-29374 EDAP TMS S.A. Parc Activite La Poudrette Lamartine 4/6 Rue du Dauphine 69120 Vaulx-en-Velin - France Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ x] Form 40-F [ ] SIGNATURES Pursuant to t ...

Revenue Performance - KIMMTRAK® net revenues reached $103.7 million in Q3 2025, a 29% increase year-over-year[1] - The company reported a total of $295.5 million in KIMMTRAK sales for the nine months ended September 30, 2025, representing a 31% increase compared to the same period in 2024[8] - The U.S. experienced an 18% year-over-year quarterly sales growth, with the mean duration of treatment increasing to 14 months[8] - European and international sales grew by 58% year-over-year, driven by increased demand and market launches[8] - Total revenue for the quarter ended September 30, 2025, was $103.693 million, a 29.2% increase from $80.248 million in the same quarter of 2024[47] - Revenue from the sale of therapies for the year to date was $295.538 million, compared to $225.937 million for the same period in 2024, reflecting a 30.7% increase[47] Expenses and Financial Loss - Research and development expenses for Q3 2025 were $70.6 million, up from $52.8 million in Q3 2024, due to advancements in autoimmune programs and Phase 3 trials[21] - Selling, general and administrative expenses increased to $39.8 million in Q3 2025 from $35.5 million in Q3 2024, primarily for business support functions[22] - The company reported a net loss of $0.2 million for Q3 2025, compared to a net profit of $8.7 million in Q3 2024[23] - The net loss for the quarter was $177,000, compared to a net income of $8.736 million in the same quarter of 2024[47] - The basic net loss per share for the quarter was $(0.00), compared to a basic net income per share of $0.17 in the prior year[47] Cash and Assets - Cash, cash equivalents, and marketable securities totaled $892 million as of September 30, 2025, up from $820.4 million at the end of 2024[24] - Total current assets amounted to $1,022,848,929, an increase from $1,009,506,000[48] - Cash and cash equivalents reached $498,413,000, up from $455,731,000[48] - Total assets increased to $1,102,500,000 from $1,009,506,000[48] - Total equity for shareholders was $396,564,360, an increase from $716,000[48] Liabilities - Total liabilities stood at $705,936,000, compared to $648,790,000 previously[48] - Current liabilities totaled $170,353,221, an increase from $181,000[48] - Accounts payable decreased to $22,956,000 from $25,100,000[48] - Deferred revenue, current, was reported at $582,000, compared to $547,000[48] Clinical Trials and Product Development - The company is advancing three Phase 3 melanoma trials and multiple mid-stage programs to enhance patient outcomes and shareholder value[2] - The Independent Data Monitoring Committee recommended a 160 mcg dose for the brenetafusp in the Phase 3 PRISM-MEL-301 trial[8] - KIMMTRAK has been approved for treatment in multiple regions, including the United States, European Union, Canada, Australia, and the United Kingdom[36] - The company is focused on expanding KIMMTRAK's indications and global market presence, targeting advanced cutaneous melanoma and adjuvant uveal melanoma[45] Patient Outcomes and Side Effects - 89% of patients receiving KIMMTRAK experienced Cytokine Release Syndrome (CRS), with 0.8% classified as grade 3 or 4[37] - Skin reactions occurred in 91% of patients treated with KIMMTRAK, necessitating monitoring and potential treatment[38] - Elevations in liver enzymes were reported in 65% of patients treated with KIMMTRAK, requiring careful monitoring[39] Cash Flow Activities - Net cash provided by operating activities decreased to $21,943,000 from $40,012,000 year-over-year[50] - Net cash used in investing activities significantly decreased to $(15,460,000) compared to $(351,589,000) in the prior year[50] - Net cash provided by financing activities decreased to $8,087,000 from $395,392,000 year-over-year[50] - Cash and cash equivalents at the beginning of the period were $455,731,000, an increase from $442,626,000 in the previous year[50] - Cash and cash equivalents at the end of the period (September 30) were $498,413,000, down from $537,767,000 in the previous year[50] - Net foreign exchange difference on cash held increased to $28,112,000 from $11,326,000 year-over-year[50]